Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Liabilities (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Total Liabilities for 7 consecutive years, with $66.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 27.59% to $66.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.0 million through Dec 2025, up 27.59% year-over-year, with the annual reading at $66.0 million for FY2025, 27.59% up from the prior year.
  • Total Liabilities hit $66.0 million in Q4 2025 for Eton Pharmaceuticals, down from $81.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $81.4 million in Q3 2025 to a low of $9.2 million in Q2 2021.
  • Historically, Total Liabilities has averaged $26.5 million across 5 years, with a median of $14.4 million in 2023.
  • Biggest five-year swings in Total Liabilities: fell 7.7% in 2021 and later surged 323.26% in 2025.
  • Year by year, Total Liabilities stood at $9.8 million in 2021, then grew by 21.53% to $12.0 million in 2022, then skyrocketed by 36.07% to $16.3 million in 2023, then skyrocketed by 217.87% to $51.7 million in 2024, then grew by 27.59% to $66.0 million in 2025.
  • Business Quant data shows Total Liabilities for ETON at $66.0 million in Q4 2025, $81.4 million in Q3 2025, and $77.7 million in Q2 2025.